Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Niraparib significantly improves outcomes for ovarian cancer patients

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.16
Views: 1423
Rating:

Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark

Dr Mirza speaks to ecancer at ESMO 2016 about results from the NOVA trial of niraparib, a PARP inhibitor, to treat platinum sensitive recurrent ovarian cancer.

Dr Mirza describes the significant extension of progression free survival in all patient subgroups assessed through the trial, hailing it as a 'break through'.

The results were published simultaneously to the conference in the New England Journal of Medicine.

Video of the press conference is available here.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation